Trillium Asset Management LLC Makes New Investment in Stryker Corporation $SYK

Trillium Asset Management LLC acquired a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 71,991 shares of the medical technology company’s stock, valued at approximately $22,666,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in SYK. VanderPol Investments L.L.C. increased its holdings in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares during the last quarter. KCM Investment Advisors LLC lifted its holdings in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC lifted its holdings in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC boosted its position in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, West Michigan Advisors LLC increased its holdings in shares of Stryker by 0.4% in the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock valued at $2,631,000 after purchasing an additional 30 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 665,370 shares of company stock valued at $216,238,501 over the last quarter. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

SYK has been the topic of several research analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a report on Friday, May 1st. BTIG Research lowered their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Raymond James Financial set a $370.00 price objective on Stryker in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Trading Down 3.5%

Shares of NYSE:SYK opened at $327.97 on Friday. The business’s 50 day simple moving average is $326.64 and its 200 day simple moving average is $332.66. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $125.80 billion, a P/E ratio of 33.99, a P/E/G ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.